Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1,3,5-triazine family

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 2, 2010, Pages 458-460

  Sun, Daekyu ^a   Melman, Galina ^b   LeTourneau, Nickolas J ^b   Hays, Allison M ^a   Melman, Artem ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b CLARKSON UNIVERSITY   (United States)

Author keywords

Antiproliferative; Cancer; Chelation; Cytotoxic; DFO; DFX; Hydroxamate; Hydroxylamine; Iron; Triazine

Indexed keywords

2,6 BIS(HYDROXYAMINO) 1,3,5 TRIAZINE; DEFERASIROX; IRON CHELATING AGENT; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PENETRATION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IRON DEPLETION; IRON DEPRIVATION CANCER THERAPY; MDA MB 231 CELL; MIAPACA CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IRON; IRON CHELATING AGENTS; TRIAZINES;

EID: 72249095175     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.130     Document Type: Article

References (27)

1. De Domenico I., Ward D.M., and Kaplan J. Nat. Rev. Mol. Cell Biol. 9 (2008) 72
2. Richardson D.R., and Baker E. Biochim. Biophys. Acta 1053 (1990) 1
3. Cerqueira N., Fernandes P.A., and Ramos M.J. Recent Patents Anti-Cancer Drug Disc. 2 1 (2007) 11
4. Hileti D., Panayiotidis P., and Hoffbrand A.V. Br. J. Haematol. 89 (1995) 181
5. Thompson H.J. Carcinogenesis 12 (1991) 111
6. Kowol C.R., Berger R., Eichinger R., Roller A., Jakupec M.A., Schmidt P.P., Arion V.B., and Keppler B.K. J. Med. Chem. 50 (2007) 1254
7. Kemp J.D., Cardillo T., Stewart B.C., Kehrberg E., Weiner G., Hedlund B., and Naumann P.W. Cancer Res. 55 (1995) 3817
8. Buss J.L., Torti F.M., and Torti S.V. Curr. Med. Chem. 10 (2003) 1021
9. Takeda E., and Weber G. Life Sci. 28 (1981) 1007
10. Dayani P.N., Bishop M.C., Black K., and Zeltzer P.M.J. Neuro-Oncol. 67 (2004) 367
11. Jiang Y., Xue Z.H., Shen W.Z., Du K.M., Yan H., Yu Y., Peng Z.G., Song M.G., Tong J.H., Chen Z., Huang Y., Lubbert M., and Chen G.Q. Leukemia 19 (2005) 1239
12. Becton D.L., and Bryles P. Cancer Res. 48 (1988) 7189
13. Pye A., and Curnow A. Photochem. Photobiol. 83 (2007) 766
14. Porter J.B., Abeysinghe R.D., Marshall L., Hider R.C., and Singh S. Blood 88 (1996) 705
15. Regino C.A.S., Torti S.V., Ma R., Yap G.P.A., Kreisel K.A., Torti F.M., Planalp R.P., and Brechbiel M.W. J. Med. Chem. 48 (2005) 7993
16. Zhao R., Planalp R.P., Ma R., Greene B.T., Jones B.T., Brechbiel M.W., Torti F.M., and Torti S.V. Biochem. Pharmacol. 67 (2004) 1677
17. Kalinowski D.S., Sharpe P.C., Bernhardt P.V., and Richardson D.R. J. Med. Chem. 50 (2007) 6212-6225
18. Bemhardt P.V., Sharpe P.C., Islam M., Lovejoy D.B., Kalinowski D.S., and Richardson D.R. J. Med. Chem. 52 (2009) 407-415
19. Valko M., Rhodes C.J., Moncol J., Izakovic M., and Mazur M. Chem. Biol. Interact. 160 (2006) 1
20. Gun J., Ekeltchik I., Lev O., Shelkov R., and Melman A. Chem. Commun. (2005) 5319
21. Ekeltchik I., Gun J., Lev O., Shelkov R., and Melman A. Dalton Trans. (2006) 1285
22. Chelators 3a,c and their iron complexes have been reported in the Ref. 21.
23. 3NHOH hydrochloride (120 mmol) and NaOH (5.4 g, 108 mmol) in water (20 mL). The reaction mixture was stirred for 14 h, diluted with water and the precipitated 3a-d were collected by filtration and recrystallized from isopropanol.
24. 1H NMR (400 MHz).
25. 3) 3.31 (s, 3H), 3.34 (s, 3H), 3.70-3.78 (m, 8H) 3.76 (s, 3H).
26. Melman G., Vimal P., and Melman A. Inorg. Chem 48 (2009) 8662
27. The 2:1 3a-iron complex was prepared according to the procedure described in Ref. 20.